iShares Biotechnology ETF (NASDAQ:IBB) vs. Equus Total Return (NYSE:EQS) Head-To-Head Survey

Equus Total Return (NYSE:EQS) and iShares Biotechnology ETF (NASDAQ:IBB) are both finance companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Equus Total Return and iShares Biotechnology ETF”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equus Total Return	$250,000.00	59.80	$12.95 million	($0.50)	-2.20
iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A

Equus Total Return has higher revenue and earnings than iShares Biotechnology ETF.

Profitability

This table compares Equus Total Return and iShares Biotechnology ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Equus Total Return	-621.28%	-7.73%	-3.63%
iShares Biotechnology ETF	N/A	N/A	N/A

Insider and Institutional Ownership

62.5% of iShares Biotechnology ETF shares are owned by institutional investors. 30.6% of Equus Total Return shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Equus Total Return has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, iShares Biotechnology ETF has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Equus Total Return and iShares Biotechnology ETF, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equus Total Return	0	0	0	0	0.00
iShares Biotechnology ETF	0	7	10	0	2.66

iShares Biotechnology ETF has a consensus target price of $136.61, indicating a potential upside of 0.00%. Given iShares Biotechnology ETF’s stronger consensus rating and higher possible upside, analysts clearly believe iShares Biotechnology ETF is more favorable than Equus Total Return.

Summary

iShares Biotechnology ETF beats Equus Total Return on 7 of the 10 factors compared between the two stocks.

About Equus Total Return

Equus Total Return, Inc. is a business development company (BDC) specializing in leveraged buyouts, management buyouts, corporate partnerships/joint ventures, growth and expansion capital, acquisition financing, roll-up acquisition strategies, operational turnarounds, recapitalizations of existing businesses, special situations, equity and equity-oriented securities issued by privately owned companies, debt securities including subordinate debt, debt convertible into common or preferred stock, or debt combined with warrants and common and preferred stock, and preferred equity financing. It invests in small to mid-sized companies and acts as a lead investor. It invests in technology, telecommunication, financial services, natural resource and industrial manufacturing and services. It invests in companies engaged in the alternative energy, real estate, healthcare, education, e-learning, leisure and entertainment, and foreign investment sector in the United States, China, India, and Europe. It investments include common and preferred stock, debt convertible into common or preferred stock, debt combined with warrants and options, and other rights to acquire common or preferred stock. It seeks to invest in companies between $1 million to $25 million with revenues between $5 million and $150 million with EBITDA between $2 million to $50 million. It seeks to take control and non-control equity positions. Equus Total Return, Inc. was founded in 1991 and is based in Houston, Texas with additional office in Vancouver, Canada.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.